Background: Polygenic scores (PGSs) combining genetic variants found to be associated with creatinine-based estimated glomerular filtration rate (eGFR) have been applied in various study populations with different age ranges. This has shown that PGS explain less eGFR variance in the elderly. Our aim was to understand how differences in eGFR variance and the percentage explained by PGS varies between population of general adults and elderly.
Results: We derived a PGS for cystatin-based eGFR (eGFR) from published genome-wide association studies. We used the 634 variants known for eGFR and the 204 variants identified for eGFR to calculate the PGS in two comparable studies capturing a general adult and an elderly population, KORA S4 (n = 2,900; age 24-69 years) and AugUR (n = 2,272, age ≥ 70 years). To identify potential factors determining age-dependent differences on the PGS-explained variance, we evaluated the PGS variance, the eGFR variance, and the beta estimates of PGS association on eGFR. Specifically, we compared frequencies of eGFR-lowering alleles between general adult and elderly individuals and analyzed the influence of comorbidities and medication intake. The PGS for eGFR explained almost twice as much (R = 9.6%) of age-/sex adjusted eGFR variance in the general adults compared to the elderly (4.6%). This difference was less pronounced for the PGS for eGFR (4.7% or 3.6%, respectively). The beta-estimate of the PGS on eGFR was higher in the general adults compared to the elderly, but similar for the PGS on eGFR. The eGFR variance in the elderly was reduced by accounting for comorbidities and medication intake, but this did not explain the difference in R-values. Allele frequencies between general adult and elderly individuals showed no significant differences except for one variant near APOE (rs429358). We found no enrichment of eGFR-protective alleles in the elderly compared to general adults.
Conclusions: We concluded that the difference in explained variance by PGS was due to the higher age- and sex-adjusted eGFR variance in the elderly and, for eGFR, also by a lower PGS association beta-estimate. Our results provide little evidence for survival or selection bias.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210501 | PMC |
http://dx.doi.org/10.1186/s12863-023-01130-9 | DOI Listing |
Mol Cancer Ther
December 2024
Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States.
ABY-029, an anti-epidermal growth factor receptor (EGFR) Affibody® molecule conjugated to IRDye 800CW, recently underwent first-in-human testing in soft-tissue sarcoma (STS). FDA Exploratory Investigational New Drug status was obtained for the Phase 0 clinical trial in which study objectives were to determine whether biological variance ratio (BVR) of 10 was achievable, fluorescence intensity correlated with EGFR expression, and doses were well tolerated. Patients (N=12) with STS were recruited based on positive EGFR immunohistochemical staining of diagnostic biopsies.
View Article and Find Full Text PDFFront Med (Lausanne)
November 2024
Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Objective: To investigate the ability of ultrasomics to noninvasively predict epidermal growth factor receptor (EGFR) expression status in patients with hepatocellular carcinoma (HCC).
Methods: 198 HCC patients were comprised in the study ( = 138 in the training dataset and = 60 in the test dataset). EGFR expression was detected by immunohistochemistry.
Diseases
October 2024
Department of Urology, Emergency County Hospital Oradea, Strada Gheorghe Doja 65, 410169 Oradea, Romania.
BMC Nephrol
November 2024
Yazd Cardiovascular Research Centre, Non-Communicable Disease Research Institute, Shahid Sadoughi University, Jomhouri Blvd, Yazd, Iran.
Background: Chronic kidney disease (CKD) is associated with increased cardiovascular disease (CVD) risk factors and morbidity in the elderly population. This study aimed to examine the association between CKD and CVD risk factors in the elderly population of Fasa and Yazd (Shahdieh), Iran, using the data from the enrolment phase of Fasa and Shahedieh cohort studies.
Methods: We conducted a cross-sectional analytical study using data from Fasa and Shahedieh cohort studies, which enrolled 1487 and 1507 participants aged over 60 years, respectively.
Int J Obes (Lond)
November 2024
Department of Woman, Child, and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.
Objectives: Evidence linked metabolic associated steatotic liver disease (MASLD) to kidney damage with the potential contribution of the I148M variant of the Patatin-like phospholipase containing domain 3 (PNPLA3) gene. We aimed at investigating the relationship of MASLD and of its genetics with kidney function in children with obesity.
Methods: A comprehensive evaluation including genotyping for the I148M PNPLA3 polymorphism was performed in 1037 children with obesity.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!